Source: Facebook.
  • NervGen Pharma (NGEN) is granting 150,000 incentive stock options
  • Stocks are offered at C$1.99 per share for first 5 years
  • NervGen (NGEN) is a clinical biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.
  • NervGen Pharma (NGEN) is currently trading at C$1.97 as of 11:30am ET

NervGen Pharma (NGEN) announced that it is granting 150,000 incentive stock options.

The company focuses on clinical-stage biotech and is dedicated to developing a first-in-class neutoreparative drug to treat nervous system damage. The stock is offered at C$1.99 per share for five years. The incentive stock option will vest equally every three months for one year. All options are granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company’s stock option plan.

NervGen (NGEN) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.

NervGen Pharma (NGEN) is currently trading at C$1.97 as of 11:30am ET.

More From The Market Online

Manulife hires banking business’ first female CEO

Manulife Bank, operating under insurer Manulife Financial (TSX:MFC), will be led by its first female CEO, Katy Boshart, beginning next week.

76% of Canadians still believe homeownership is out of reach

Buying a home feels out of reach for most Canadians who don't own property, yet half of non-owners are still holding onto that goal.
Bank of Canada - Governor Tiff Macklem and Senior Deputy Governor, Carolyn Rogers.

Bank of Canada holds rate, keeping risk-on sentiment at bay

The Bank of Canada held its policy interest rate at 5 per cent, with the Canadian economy yet to show evidence of sustained easing.